Vesigen Therapeutics
Vesigen’s patented technology uses ARRDC1 Mediated Microvesicles (ARMMs) to deliver intracellular therapeutics to previously undruggable targets.
Last updated on
About Vesigen Therapeutics
Employees
11-50Funding / Mkt. Cap
$29MCategory
Location
City
CambridgeState
MassachusettsCountry
United StatesVesigen Therapeutics
Find your buyer within Vesigen Therapeutics
Tech Stack (36)
